scPharmaceuticals Inc. (SCPH)
SCPHDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
ceftriaxone
Pharmacokinetics in Healthy Adults
Fursemide Injection Solution for subcutaneous administration (80 mg)
Heart Failure
Furosemide injection solution for subcutaneous administration (80 mg)
Heart Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ceftriaxone | Phase 3 | Pharmacokinetics in Healthy Adults | - | - |
Fursemide Injection Solution for subcutaneous administration (80 mg) | Phase 3 | Heart Failure | - | - |
Furosemide injection solution for subcutaneous administration (80 mg) | Phase 2 | Heart Failure | - | - |
Frequently asked questions
What is in scPharmaceuticals Inc. (SCPH)'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in scPharmaceuticals Inc. (SCPH)'s (SCPH) pipeline across Phase 3, Phase 2. Its lead program is ceftriaxone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is scPharmaceuticals Inc. (SCPH)'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for scPharmaceuticals Inc. (SCPH) (SCPH) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SCPH biotech catalysts?→
Add SCPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow scPharmaceuticals Inc. (SCPH)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.